Sanara MedTech Inc. Q4 FY2025 earnings call

1. Commercial execution across three key initiatives: Strengthening relationships with independent distributors, ending 2025 with over 450 contracted distributors vs. over 350 in 2024; selling into over 1,450 healthcare facilities by end of 2025, exceeding the target; penetrating existing facility customers by adding new surgeon users across specialties. 2. Wind down of THP segment was substantially complete at end of 2025, with total cash use related to THP in second half of 2025 at 5.3 million. 3. BioSurge secured an innovative technology contract from Vizient, available to Vizient's network of healthcare facility customers starting January 1, 2026. 4. Clinical studies featuring Allocyte Plus and BioSurge were published. 5. R&D team converted 11 provisional patent applications to non-provisional filings and submitted additional provisional patent applications for Celerate RX surgical products. 6. On track to introduce OSTIC synthetic injectable bone bioadhesive to U.S. market in first quarter of 2027 through partnership with BMI.

Full year 2025: Generated net revenue of 103.1 million, representing 19% year-over-year growth. Exceeded 100 million net revenue for the first time. Fourth quarter: Generated net revenue of 27.5 million, representing 5% year-over-year growth. Excluding 1.8 million of bias surge sales related to Hurricane Helene, net revenue increased 13% year over year. Soft tissue products drove much of the growth with modest contributions from bone fusion products.

Reaffirmed full year 2026 net revenue guidance of 116 to 121 million, representing growth of approximately 13% to 17% compared to 2025. Expect first quarter 2026 net revenue to be approximately 26.7 million to 27.2 million, representing growth of approximately 14% to 16% year over year.

Q: Congrats on all the progress in the year. A question on bias surge following the vision contract effective by January 1, how much of your growth in 2026 do you think is attributable to this new volume of GPO versus organic growth in existing accounts? And do you anticipate any other of these deals to materialize in 2026?

A: The Vizient contract was significant. It will take time to educate at the facility level. Our team is working to get access into those 1800 accounts. We haven't given guidance specific to a product but think the contract gives great runway.

Q: And then if I could ask another one on Celerate Rx growth. So with this new study, cost effectiveness, do you see any opportunity for what do you think the impact on growth and maybe reimbursement in terms of cost effectiveness? And do you expect any other studies for Celerate to come out during this next year that could also bolster?

A: We believe strongly in clinical evidence specific to our anchor products. We feel confident in the economic study. We'll continue to put energy against clinical evidence, scientific, clinical and economic fronts. The economic evidence strengthens our relationships and has an impact on our numbers going forward.